Immunotherapy Drug on Clinical Trial Shrinks Neuroblastoma Tumors

by Julia Samuel on  June 3, 2016 at 4:20 PM Clinical Trials News
RSS Email Print This Page Comment bookmark
Font : A-A+

An investigational drug under trial shrank neuroblastoma tumors in 80 percent of newly diagnosed, young, high-risk patients. The immunotherapy agent was produced on the St. Jude Children's Research Hospital campus where the study is still underway.
Immunotherapy Drug on Clinical Trial Shrinks Neuroblastoma Tumors
Immunotherapy Drug on Clinical Trial Shrinks Neuroblastoma Tumors

Of the 34 children and teenage patients included in the report, 13 had completed therapy and showed no evidence of disease. Four patients have been off treatment for 18 months or more. Along with the investigational monoclonal antibody, study participants underwent multi-drug chemotherapy, surgery, radiation and autologous hematopoietic stem cell transplantation.

Thirteen patients are still receiving treatment. In addition, two patients with persistent disease received additional therapy and two patients died of treatment-related toxicities.

"The early response is very promising, among the best that we have seen against neuroblastoma, but we still have a long way to go," said first author Wayne Furman, M.D., a member of the St. Jude Department of Oncology. "Will this translate into more cures? We hope so, but the answer is several years away."

While certain patients, particularly infants, have cure rates of 90 percent or better, the outlook is worse for more than half of newly diagnosed patients whose disease has already spread widely or includes mutations in the MYCN gene. With current treatment, 50 to 60 percent of these high- risk patients are still alive three years after their disease was diagnosed.

In this study, patients began treatment with chemotherapy using cyclophosphamide and topotecan and the experimental monoclonal antibody hu14.18K322A. After two rounds of therapy, researchers reported that primary tumors were 47 to 96 percent smaller in 80 percent of patients and had stopped growing in the remaining patients. In similar patients enrolled in a previous national trial, tumor size decreased in only 40 percent of patients treated with the same drugs but without hu14.18K322A.

Hu14.18K332A is a laboratory-produced antibody designed to activate the immune response against tumor cells by recognizing and binding to an antigen found on the surface of most neuroblastoma tumor cells. The antigen, GD2, is also carried on the surface of melanoma, the bone cancer osteosarcoma and some soft-tissue sarcomas. GD2 is also found on normal peripheral nerves. Binding of anti-GD2 monoclonal antibodies to these pain fibers causes severe pain and is the major side effect of these agents.

The experimental antibody in this study was engineered to reduce the treatment-limiting pain associated with other anti-GD2 monoclonal antibodies. Hu14.18K322A includes a point mutation in the hu14.18 protein that is designed to eliminate activation of the complement cascade that is believed to trigger the treatment-related pain. The experimental antibody also has fewer mouse components and is therefore less likely to become an immune target itself.

Treatment-related pain associated with the experimental monoclonal antibody was well controlled with intravenous narcotics that began prior to therapy, Furman said.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Clinical Trials Clinical Trials - The Past and The Future Clinical Trials - Different Phases of the trial Immunisation Signature Drug Toxicity Dealing with Pollen Allergy Drugs Banned in India Placebo Effects: Rare Insights Neuroblastoma 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive